(NASDAQ: RARE) Ultragenyx Pharmaceutical's forecast annual revenue growth rate of 15.64% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.6%, and while it is forecast to beat the US market's average forecast revenue growth rate of 11.65%.
Ultragenyx Pharmaceutical's revenue in 2026 is $730,279,000.On average, 22 Wall Street analysts forecast RARE's revenue for 2026 to be $78,036,124,183, with the lowest RARE revenue forecast at $72,627,013,894, and the highest RARE revenue forecast at $82,730,746,755. On average, 22 Wall Street analysts forecast RARE's revenue for 2027 to be $101,504,140,840, with the lowest RARE revenue forecast at $84,163,799,151, and the highest RARE revenue forecast at $175,207,472,892.
In 2028, RARE is forecast to generate $112,829,943,276 in revenue, with the lowest revenue forecast at $84,503,206,297 and the highest revenue forecast at $164,403,521,684.